Stand der Therapiestrategien bei älteren Myelom-Patienten

Zusammenfassung

In Turin trafen sich in diesem Jahr zum ersten Mal Ärzte und Wissenschaftler, die sich mit dem multiplen Myelom befassen, auf dem European Myeloma Network Meeting. Im Fokus standen unter anderem der Stellenwert der autologen Stammzelltransplantation und die Behandlung des älteren Patienten mit neu diagnostiziertem multiplen Myelom (NDMM).

 

• Literatur

• 1 Cavo M. et al. Autologous stem cell transplantation versus bortezomib-melphalan-prednisone for newly diagnosed multiple myeloma: Second interim analysis of the phase 3 EMN02/HO95 study.. ASH. 2017. Abstract 397
• 2 Attal M. et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma.. N Engl J Med 2017; 376: 1311-1320
• 3 Cavo M. et al. Double autologous stem cell transplantation significantly prolongs progression-free survival and overall survival in comparison with single autotransplantation in newly diagnosed multiple myeloma: An analysis of phase 3 EMN02/HO95 study. ASH. 2017. Abstract 401
• 4 Garderet L. et al. Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: A prospective multicenter study.. Haematologica 2016; 101: 1390-1397
• 5 Larocca A. et al. Impact of bortezomibor lenalidomidebased induction treatment on high risk cytogenetic transplant-ineligible patients with newly diagnosed multiple myeloma enrolled in the GIMEMA-MM-03–05 and EMN01 trials. ASH. 2017. Abstract 744
• 6 Dimopoulos MA. et al. Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit.. J Clin Oncol 2016; 34: 1544-1557
• 7 San Miguel JF. et al. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.. J Clin Oncol 2013; 31: 448-455
• 8 Facon T. et al. Final analysis of overall survival from the FIRST trial. ASH. 2016. Abstract 241
• 9 Clegg A. et al. Frailty in elderly people.. Lancet 2013; 381: 752-762
• 10 Palumbo A. et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: An International Myeloma Working Group report.. Blood 2015; 25: 2068-2074
• 11 Larocca A. et al. Patient-centered practice in elderly myeloma patients: An overview and consensus from the European Myeloma Network (EMN). Leukemia. 2018. Apr 25. doi: 10.1038/s41375–018–0142–9. [Epub ahead of print]